Many thanks to JAYPEEDIGITAL platform, which has been an indispensable easy-to-use source for our...Ozlem YALCINKAYA
Jaypeedigital site offers to our students a huge number of medical publications such as textbooks...Dr Jesus Tapia Jurado
With user-friendly interface, Jaypeedigital provides extensive coverage in medicine, dentistry and...Wan Suhaimi Ariffin, MLS (Syracuse), BLS (UITM)`
Jaypeedigital platform presents an interesting and valuable collection of medical publications that...David E. García Díaz (MD)
Some of us teach in the Division of Graduate Studies and Research at the Faculty and the contents of...Arcelia Meléndez Ocamp (MD)
Subscribe to be the first to know about Best Deals and Exclusive Offers!
JOURNAL TITLE: Euroasian Journal of Hepato-Gastroenterology
Background: Graft macrosteatosis can predispose to a higher risk of graft loss so we sought to redefine acceptable cutoffs for graft steatosis. Methods: Data of 26,103 donors who underwent liver transplantation (LT) between January 2004 and December 2018 from the UNOS-STAR database were utilized. A high-risk steatotic (HRS) graft and a low-risk steatotic (LRS) graft were defined as ≥20% and <20% macrosteatosis, respectively. High-risk steatotic grafts were further classified as grafts with 20–29% (G1S grafts), 30–39% (G2S grafts), and ≥40% steatosis (G3S grafts). Outcomes between groups were compared. Results: LRS grafts had excellent graft (93.3 and 87.7%) and overall survival (95.4 and 90.5%) at 90 days and 1 year. Compared to LRS grafts, G1S, G2S, and G3S grafts had worse graft and overall survival at 90 days and 1-year (p <0.001). There was no difference in graft or overall survival of G1S or G3S grafts compared to G2S grafts until after adjustment in which G3S grafts were found to be associated with an increased risk of graft loss—aHR 1.27 (1.03–1.57), p = 0.02. Discussion: Liver grafts can be categorized into three categories: (1) <20% or “very low risk”, (2) 20–39% or “low-to-moderate risk”, and usually acceptable, and (3) ≥40% steatosis or “moderate-to-high risk”.
© 2019 Jaypee Brothers Medical Publishers (P) LTD. | All Rights Reserved